Literature DB >> 30186052

Small Bowel and Colorectal Carcinoids.

Raphael M Byrne1, Rodney F Pommier2.   

Abstract

Neuroendocrine tumors, or carcinoid tumors, of both the midgut and hindgut are quite rare, but their incidence is increasing. Surgery is the treatment of choice in patients who can tolerate an operation and have operable disease. Options for the treatment of metastatic disease include cytoreductive surgery, somatostatin analogues, interferon α, local liver therapies (hepatic arterial embolization, ablation), chemotherapy, Peptide-Receptor Radionucleotide Radiotherapy, angiogenesis inhibitors, and mammalian target of rapamycin inhibitors.

Entities:  

Keywords:  appendiceal NET; carcinoid tumors; colorectal NET; jejunoileal NET; neuroendocrine tumors

Year:  2018        PMID: 30186052      PMCID: PMC6123011          DOI: 10.1055/s-0038-1642054

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  35 in total

1.  ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.

Authors:  Ulrich-Frank Pape; Aurel Perren; Bruno Niederle; David Gross; Thomas Gress; Frederico Costa; Rudolf Arnold; Timm Denecke; Ursula Plöckinger; Ramon Salazar; Ashley Grossman
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Carcinoid tumors of the rectum: a multi-institutional international collaboration.

Authors:  Conor J Shields; Emmanuel Tiret; Desmond C Winter
Journal:  Ann Surg       Date:  2010-11       Impact factor: 12.969

3.  Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.

Authors:  M A Kinney; M E Warner; D M Nagorney; J Rubin; D R Schroeder; P M Maxson; M A Warner
Journal:  Br J Anaesth       Date:  2001-09       Impact factor: 9.166

4.  Gastrointestinal carcinoids: an increasing incidence of rectal distribution.

Authors:  Paul Avenel; Alasdair McKendrick; Sumet Silapaswan; Ramachandra Kolachalam; William Kestenberg; Lorenzo Ferguson; Michael J Jacobs; Yousif Goriel; Vijay Mittal
Journal:  Am Surg       Date:  2010-07       Impact factor: 0.688

Review 5.  Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Authors:  R Garcia-Carbonero; J Capdevila; G Crespo-Herrero; J A Díaz-Pérez; M P Martínez Del Prado; V Alonso Orduña; I Sevilla-García; C Villabona-Artero; A Beguiristain-Gómez; M Llanos-Muñoz; M Marazuela; C Alvarez-Escola; D Castellano; E Vilar; P Jiménez-Fonseca; A Teulé; J Sastre-Valera; M Benavent-Viñuelas; A Monleon; R Salazar
Journal:  Ann Oncol       Date:  2010-02-05       Impact factor: 32.976

6.  The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum.

Authors:  Lowell B Anthony; Jonathan R Strosberg; David S Klimstra; William J Maples; Thomas M O'Dorisio; Richard R P Warner; Gregory A Wiseman; Al B Benson; Rodney F Pommier
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

7.  Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma.

Authors:  Michihiro Koizumi; Masahiko Onda; Noritake Tanaka; Tomoko Seya; Takeshi Yamada; Yoshiyuki Takahashi
Journal:  Digestion       Date:  2002       Impact factor: 3.216

8.  The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.

Authors:  Ursula Ploeckinger; Guenter Kloeppel; Bertram Wiedenmann; Ruediger Lohmann
Journal:  Neuroendocrinology       Date:  2009-09-23       Impact factor: 4.914

Review 9.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

10.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

View more
  8 in total

1.  Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases.

Authors:  Steven D Scoville; Dimitrios Xourafas; Aslam M Ejaz; Allan Tsung; Timothy Pawlik; Jordan M Cloyd
Journal:  World J Gastrointest Surg       Date:  2020-04-27

Review 2.  Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.

Authors:  R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2022-08-30       Impact factor: 5.467

Review 3.  Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Andrew Canakis; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

4.  Metastatic neuroendocrine tumor with metastases to the right liver in a patient with absent left portal vein.

Authors:  Reid C Mahoney; Kyrillos Awad; Gregorio Maldini
Journal:  J Surg Case Rep       Date:  2021-05-27

Review 5.  Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors.

Authors:  James Y Lim; Rodney F Pommier
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-26       Impact factor: 5.555

6.  Factors associated with worse outcomes for colorectal neuroendocrine tumors in radical versus local resections.

Authors:  Osayande Osagiede; Elizabeth Habermann; Courtney Day; Emmanuel Gabriel; Amit Merchea; Riccardo Lemini; Iktej S Jabbal; Dorin T Colibaseanu
Journal:  J Gastrointest Oncol       Date:  2020-10

7.  Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor - an update on neuroendocrine neoplasm's treatment: A case report.

Authors:  Oriol Mirallas; Nadia Saoudi; Diego Gómez-Puerto; Mar Riveiro-Barciela; Xavier Merino; Cristina Auger; Stefania Landolfi; Laia Blanco; Amparo Garcia-Burillo; Xavier Molero; Maria Teresa Salcedo-Allende; Jaume Capdevila
Journal:  World J Hepatol       Date:  2021-05-27

8.  A Case of Profound Secretory Diarrhea Revealing 2 Primary Neuroendocrine Tumors.

Authors:  Ashley A Thompson; Fathima K Suhail; Kanish Mirchia; Sekou R Rawlins
Journal:  ACG Case Rep J       Date:  2021-07-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.